Background B-cell maturation antigen (BCMA)–directed chimeric antigen receptor (CAR) T-
cell therapies have generated responses in patients with advanced myeloma, but relapses …

Introduction: CAR T cell therapies targeting B-cell maturation antigen (BCMA) have resulted
in unprecedented depth and duration of response in R/R MM. However, relapses are …

Background Chimeric antigen receptor (CAR) T-cell therapy targeting B-cell maturation
antigen (BCMA) has shown activity in treating relapsed or refractory multiple myeloma; …

Early clinical results of chimeric antigen receptor (CAR) T cell therapy targeting B cell
maturation antigen (BCMA) for multiple myeloma (MM) appear promising, but relapses …

PURPOSE G protein–coupled receptor, class C group 5 member D (GPRC5D) is considered
to be a promising surface target for multiple myeloma (MM) immunotherapy. Here, we report …

Anti-multiple myeloma B cell maturation antigen (BCMA)-specific chimeric antigen receptor
(CAR) T-cell therapies represent a promising treatment strategy with high response rates in …

B-cell maturation antigen (BCMA)-specific chimeric antigen receptor (CAR) T-cell therapies
have shown efficacy in relapsed/refractory multiple myeloma (RRMM). Because the non …

Chimeric antigen receptor (CAR) T-cell therapy for multiple myeloma targeting B-cell
maturation antigen (TNFRSF17; BCMA) induces high overall response rates; however …

Background Anti-B-cell maturation antigen (BCMA) chimeric antigen receptor T-cell (CAR T)
therapy showed remarkable efficacy in patients with relapsed or refractory multiple myeloma …

B cell maturation antigen (BCMA) target loss is considered to be a rare event that mediates
multiple myeloma (MM) resistance to anti-BCMA chimeric antigen receptor T cell (CAR T) or …